Polyarticular Juvenile Idiopathic Arthritis
FDA approves Kevzara for polyarticular juvenile idiopathic arthritis
The FDA has approved the interleukin-6 inhibitor Kevzara for the treatment of polyarticular juvenile idiopathic arthritis, according to a press release from Regeneron Pharmaceuticals and Sanofi.
Children with arthritis exhibit greater internal, psychological disturbances
Children with spondyloarthritis and polyarticular arthritis demonstrate greater internalized disturbances and worse psychological functioning in school and social arenas, according to data.
STOP-JIA: 'Early combination' DMARD, biologic may improve key outcomes in polyarticular JIA
Three strategies aimed at starting patients with polyarticular juvenile idiopathic arthritis on different combinations of DMARDs and biologics resulted in similar rates of clinically inactive disease without glucocorticoids at 12 months, according to data.
Adalimumab well-tolerated by most children with polyarticular JIA
Adalimumab, with or without methotrexate, is well-tolerated over a period of at least 7 years among most children with polyarticular-course juvenile idiopathic arthritis, according to data published Arthritis Care & Research.